Physician profile
Marc D Rosenberg
NPI 1427033083
$12,976.43
in general payments reported to CMS, 2019-2025
41 companies · $3,757 in 2025
The $3,757 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,555 · 2020: $748 · 2021: $1,061 · 2022: $1,676 · 2023: $2,155 · 2024: $2,026 · 2025: $3,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,782 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,782.34 |
| Education | $154.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,844.52 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Janssen Biotech, INC. | $1,264.36 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,141.17 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $947.64 | 2019-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $771.09 | 2022-2025 | Dupixent |
| Genzyme Corporation | $677.38 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $646.48 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $458.45 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $407.76 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $373.23 | 2023-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $304.87 | 2019-2024 | Linzess |
| Ardelyx, INC. | $289.25 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $259.40 | 2019-2024 | Dificid, Zinplava |
| Novo Nordisk INC | $239.68 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $214.29 | 2024-2025 | Iqirvo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $192.68 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $180.29 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $154.28 | 2023-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $153.10 | 2019-2021 | |
| Pfizer INC. | $151.65 | 2019-2025 | |
| Medtronic USA, INC. | $148.19 | 2019 | |
| Aimmune Therapeutics, INC. | $146.75 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $134.24 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Gilead Sciences, INC. | $127.52 | 2019-2025 | Livdelzi |
| Medtronic, INC. | $116.21 | 2022 | |
| Dova Pharmaceuticals | $95.71 | 2019 | |
| Mallinckrodt Hospital Products INC. | $73.76 | 2025 | Terlivaz |
| Nestle Healthcare Nutrition INC. | $70.59 | 2022-2023 | |
| Vivus LLC | $60.58 | 2021-2025 | Pancreaze |
| Regeneron Pharmaceuticals, INC. | $59.71 | 2023 | Dupixent |
| Ucb, INC. | $57.23 | 2019-2020 | |
| Allergan, INC. | $36.22 | 2019 | |
| Alfasigma USA, INC. | $31.13 | 2020-2021 | |
| Daiichi Sankyo INC. | $27.14 | 2023 | Injectafer |
| Ferring Pharmaceuticals INC. | $24.86 | 2020-2021 | |
| Braintree Laboratories, INC. | $18.24 | 2020 | |
| Axonics, INC. | $18.24 | 2024 | Axonics |
| Curium US LLC | $17.99 | 2022 | |
| Evoke Pharma, INC. | $15.01 | 2022 | |
| Redhill Biopharma INC. | $13.01 | 2020 | |
| Organon LLC | $12.53 | 2025 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.